Evidence map›Paper›PMID 36376805›Full record

ArticleBMC ophthalmology2022

Ocular surface disorders affect quality of life in patients with autoimmune blistering skin diseases: a cross-sectional study.

Huanmin Kang, Mengbo Wu, Jianing Feng, Yuerong Ren, Yingyi Liu, Wen Shi, Yingqian Peng, Yixin Tan, Ruifang Wu, Guiying Zhang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Huanmin Kang *Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Mengbo Wu *Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Jianing FengDepartment of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Yuerong RenDepartment of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Yingyi LiuDepartment of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Wen ShiDepartment of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Yingqian PengDepartment of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Yixin TanDepartment of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Ruifang WuDepartment of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Guiying ZhangDepartment of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yan HeDepartment of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. yanhe6416@csu.edu.cn.
Second Xiangya Hospital of Central South University · CNCentral South University · CNHunan Provincial Center for Disease Control and Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAutoimmune blistering skin diseases (AIBD) are a group of rare chronic autoimmune diseases which are associated with ocular surface diseases especially dry eye disease. This study is designed to investigate the relationship between ocular surface disorders and quality of life among patients with autoimmune blistering skin diseases.

methodsTwenty-four AIBD patients (18 pemphigus and 7 pemphigoid) and twenty-five non-AIBD controls were included. Ocular surface disease index (OSDI), ocular surface evaluation, including slit-lamp examination, Schirmer I test, tear break-up time, corneal fluorescein staining, lid-parallel conjunctival folds, meibomian gland evaluation, presence of symblepharon and corneal opacity were assessed. Life quality was evaluated by multiple questionnaires, including Medical Outcomes Study 36-Item Short Form Questionnaire (SF-36), Hospital Anxiety and Depression Scale (HADS), Pittsburgh Sleep Quality Index (PSQI) and Health Assessment Questionnaire-Disability Index (HAQ-DI). Ocular surface tests and quality of life were compared between AIBD patients and non-AIBD controls. In the AIBD patients, the associations between ocular surface parameters and quality of life were also evaluated.

results92% of AIBD patients and 87.5% of age- and sex-matched non-AIBD controls were diagnosed with dry eye in this study. Compared with non-AIBD controls, AIBD patients reported lower SF-36 scores (P < 0.05) and severer OSDI, Schirmer I test, tear break-up time, corneal fluorescein staining, presence of symblepharon and corneal opacity measures (P < 0.05). OSDI, Schirmer I test were correlated with SF-36 composite scores or scores on the SF-36 subscales.

conclusionsAIBD patients experience reduced quality of life and more severe ocular surface disorders including dry eye, symblepharon and corneal opacity. Early treatments of dry eye and collaborations among multidisciplinary physicians are necessary in patients with AIBD.

Indexed as

Autoimmune DiseasesCorneal OpacityDry Eye SyndromesEyelid DiseasesSkin DiseasesBlisterCross-Sectional StudiesFluoresceinHumansMeibomian GlandsQuality of LifeSurveys and QuestionnairesTearsFluoresceinAutoimmune skin diseasesDry eyeOcular surfaceQuality of lifeQuestionnaire

Identifiers

PMID36376805
PMCPMC9664680
OpenAlexW4308986109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.